PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
Li-Li LongSi-Cong MaZe-Qin GuoYan-Pei ZhangZhenzhen FanLi-Juan LiuLi LiuDuan-Duan HanMeng-Xin LengJian WangXue-Jun GuoJia-Le TanXiao-Ting CaiYan LinXinghua PanDe-Hua WuXue BaiZhong-Yi DongPublished in: Cancer research (2023)
Targeting PARP exerts dual effects to overcome LKB1 loss-driven immunotherapy resistance through triggering DNA damage and adaptive immunity, providing a rationale for dual PARP and PD-1 inhibition in treating LKB1-mutant lung cancers.